Ibritumomab Tiuxetan in Lymphomaenglish
ID: 6-17 Nov 2013
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
Adult patients with non-Hodgkin’s lymphoma of any type, at any stage of disease, and for any level of performance status.
In patients with lymphoma of any type or stage:
- What is the role of yttrium-90 (90Y) ibritumomab tiuxetan? Outcomes of interest include survival, quality of life, time-to-progression, response duration, response rate, and toxicity.
- Which patients are more or less likely to benefit from treatment with 90Y-ibritumomab tiuxetan?
- Is performance of imaging or dosimetry required for therapy to be safe and effective?
Full Report (PDF) (866.95 KB)